
1st treatment
Dose (μg/kg)/infusion time (h)/infusion rate

2nd treatment
Dose (μg/kg)/infusion time (h)/infusion rate


Group 1

Volunteer 1

500/2/constant

_

Volunteer 2

500/2/constant

Volunteer 3

500/2/constant

Group 2

Volunteer 1

1000/2/constant

2500/2/constant
^{H}

Volunteer 2

1000/2/constant

2500/2/constant
^{H}

Volunteer 3

1000/2/constant

–

Volunteer 4

1000/2/constant

2500/2/constant
^{H}

Group 3

Volunteer 1

1000/1/constant
^{h}

1000/2/const. rate

Volunteer 2

1000/1/constant

1000/2/const. rate

Volunteer3

1000/1/constant

1000/2/const. rate

Group 4

Volunteer 1

1500/2/constant

2500/2/const. rate
^{H}

Volunteer 2

1500/2/constant
^{h}

2500/2/const. rate
^{H}

Volunteer 3

1500/2/constant

–

Volunteer 4

1500/2/constant

2500/2/const. rate
^{H}

Group 5

Volunteer 1

2000/2/constant
^{h}

–

Volunteer 2

2000/2/constant

Volunteer 3

2000/2/constant
^{h}

Volunteer 4

2000/2/constant
^{h}

Volunteer 5

2000/2/constant
^{h}

Volunteer 6

2000/2/constant
^{h}

Group 6

Volunteer 1

2000/2/ramped

–

Volunteer 2

2000/2/ramped
^{h}

Volunteer 3

2000/2/ramped

Group 7

Volunteer 1

2500/2/constant
^{H}

–

Volunteer 2

2500/2/constant^{H}

1500/2/const. rate

Volunteer 3

2500/2/constant^{H}

1500/2/const. rate

Volunteer 4

2500/2/constant^{H}

1500/2/const. rate

 A total of 27 volunteers were treated with 39 doses of balixafortide
 In italics volunteers with histamine release associated AE

^{H}Antihistamine premedication

^{h}
Therapeutic antihistamine treatment upon appearance of likely histamine release AEs